Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial (NCT05554341)
Nilotinib and Paclitaxel in Patients With Prior Taxane-Treated Solid Tumors: A ComboMATCH Treatment Trial
🩺 Plain-English Summary (8th-Grade Level)
This phase II ComboMATCH treatment trial evaluates nilotinib with paclitaxel for the treatment of patients with solid cancers that are growing, spreading, or getting worse (progressive) and that have previously been treated with taxane therapies. Nilotinib is in a class of medications called kinase inhibitors. It works by binding to and blocking the action of a protein called ABL, which signals tumor cells to multiply. This helps slow or stop the proliferation of tumor cells. Paclitaxel is a drug that blocks cell growth by stopping cell division and it may kill tumor cells. Giving nilotinib with paclitaxel may be effective at treating patients with progressive solid cancers that have previously been treated with taxane therapies.
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (124 Sites)
Showing the first 25 of 124 sites.
- University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Kingman Regional Medical Center — Kingman, Arizona
- Stanford Cancer Institute Palo Alto — Palo Alto, California
- Presbyterian Intercommunity Hospital — Whittier, California
- UCHealth University of Colorado Hospital — Aurora, Colorado
- UM Sylvester Comprehensive Cancer Center at Aventura — Aventura, Florida
- UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
- University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
- UM Sylvester Comprehensive Cancer Center at Kendall — Miami, Florida
- UM Sylvester Comprehensive Cancer Center at Plantation — Plantation, Florida
- Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
- Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
- Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
- Saint Alphonsus Cancer Care Center-Nampa — Nampa, Idaho
- Kootenai Clinic Cancer Services - Post Falls — Post Falls, Idaho
- Kootenai Clinic Cancer Services - Sandpoint — Sandpoint, Idaho
- Advocate Good Shepherd Hospital — Barrington, Illinois
- Illinois CancerCare-Bloomington — Bloomington, Illinois
- Illinois CancerCare-Canton — Canton, Illinois
- Illinois CancerCare-Carthage — Carthage, Illinois
- Centralia Oncology Clinic — Centralia, Illinois
- Northwestern University — Chicago, Illinois
- John H Stroger Jr Hospital of Cook County — Chicago, Illinois
- Advocate Illinois Masonic Medical Center — Chicago, Illinois
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Malignant Solid Neoplasm
- Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors — Houston, Texas
- Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors — Boston, Massachusetts
- Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression — Houston, Texas
- Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer — Phoenix, Arizona
- Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors — Sacramento, California
Explore by condition: All Metastatic Malignant Solid Neoplasm clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.